Analysts have clear opinions on EDIT.

There are 3 analysts on the Wall offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $43.00 with a high forecast of $55.00 and a low forecast of $31.00. The average price target represents a 63.50% increase from the last price of $26.30.
Editas Medicine, Inc. (EDIT) is followed by 3 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Editas Medicine, Inc.(EDIT) do ?
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

Editas Medicine, Inc. (EDIT) Insider Trades

Multiple company employees have indulged in significant insider trading. Editas Medicine, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Chief Scientific Officer, Albright Charles : S – Sale+OE(-$16,763) of EDIT in the trading session of 2020-02-07.

Chief Scientific Officer Albright Charles : S – Sale+OE(-$147,288) of EDIT in the trading session of 2020-02-03.

CEO Collins Cynthia : S – Sale(-$134,135) of Editas Medicine, Inc. in the trading session of 2019-08-19.

Looking for stocks just like EDIT?

Based on Wall Street analyst research, several stocks are similar to EDIT
They are:
– ADVM [Info can be found here: ]
– SGMO [Info can be found here: ]
– BLUE [Info can be found here: ]